Ribociclib plus letrozole in patients with hormone receptor‐positive, HER2‐negative advanced breast cancer with no prior endocrine therapy: subgroup analysis from the phase 3b CompLEEment‐1 trial: Subgroup analysis of the CompLEEment‐1 trial. Radiology and Oncology, v. 56, n. 2, p. 238–247, 3 Jul.2022.